Point-of-Care (POC) Coagulation Testing Global Market Report 2024

The point-of-care (POC) coagulation testing market size has grown strongly in recent years. It will grow from $1.12 billion in 2023 to $1.18 billion in 2024 at a compound annual growth rate (CAGR) of 5.9%. The growth in the historic period can be attributed to several factors, including the rise in patient demand, the growing trend of point-of-care testing, the high reliability of coagulation status on PT tests, automation, and integration with electronic health records (EHRs), as well as the rising incidence of cardiovascular diseases and blood disorders.

The point-of-care (POC) coagulation testing market size is expected to see steady growth in the next few years. It will grow to $1.42 billion in 2028 at a compound annual growth rate (CAGR) of 4.6%. The forecasted growth is driven by expanding applications in healthcare, increasing demand in homecare settings, and the rising prevalence of chronic blood disorders. Patient demand for rapid and accurate testing, along with the increase in point-of-care testing, also contribute to this growth. Major trends in the forecast period include technological advancements, high demand in developed countries, expanding applications in healthcare, the impact of COVID-19, and the use of multiplexing in point-of-care diagnostics.

The point-of-care (POC) coagulation testing market is expected to grow due to the increasing incidence of cardiovascular diseases (CVDs). CVDs encompass a range of disorders affecting the heart and blood vessels, such as coronary heart disease and cerebrovascular disease. POC coagulation testing plays a crucial role in CVD treatment by providing real-time information on coagulation status, enabling timely interventions and reducing the risk of bleeding complications, particularly after cardiac surgery. For example, in May 2023, the Centers for Disease Control and Prevention reported that heart disease claimed about 695,000 lives in the United States in 2021, accounting for 1 in 5 deaths. Coronary heart disease, the most common type, caused 375,476 deaths in 2021. This increasing prevalence of cardiovascular diseases is a key driver behind the growth of the POC coagulation testing market.

Major companies in the point-of-care (POC) coagulation testing market are concentrating on strategic collaborations to enhance their competitive position. These collaborations involve formal agreements between two or more parties to work towards specific, mutually beneficial goals. For example, in October 2021, Trivitron Healthcare partnered with Diagon Ltd. and Vanguard Diagnostics to introduce Coagulation Analyzer products. These analyzers offer precise and efficient coagulation testing, with the collaboration aimed at enhancing patient diagnosis and management. The range of analyzers is designed to cater to various healthcare settings, making coagulation testing more accessible.

In December 2023, Roche, a Switzerland-based pharmaceutical company, acquired LumiraDx Ltd. for $350 million. This acquisition enhances Roche's diagnostics portfolio, enabling more patient-centric healthcare through point-of-care solutions that cover the entire patient journey. LumiraDx Ltd., based in the UK, specializes in point-of-care coagulation testing.

Major companies operating in the point-of-care (poc) coagulation testing market report are AT&T Corporation, Siemens Healthcare GmbH, Thermo Fisher Scientific Inc., Abbott Laboratories, F. Hoffmann-La Roche Ltd., Danaher Corporation, Medtronic Plc, Koninklijke Philips N.V., Sysmex Corporation, IDEXX Laboratories Inc., Quidel Corporation, Bio-Rad Laboratories Inc., Teleflex Incorporated, Werfen SA, Nihon Kohden Corporation, Horiba Ltd., Hycel, Nova Biomedical Corporation, Haemonetics Corporation, Maccura Biotechnology Co. Ltd., Helena Laboratories Corporation, Abaxis Inc., ARKRAY Inc., Radiometer Medical ApS, HemoSonics LLC, iLine Microsystems SL, Corgenix Medical Corporation, Quotient Limited, Micropoint Bioscience Inc., Beijing Succeeder Technology Inc., EKF Diagnostics Holdings plc.

North America was the largest region in the point-of-care (POC) coagulation testing market in 2023. The regions covered in the point-of-care (poc) coagulation testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the point-of-care (poc) coagulation testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Point-of-care (POC) coagulation testing is a diagnostic method that evaluates blood clotting function at or near the patient's location, rather than in a centralized lab. It provides rapid results, typically within minutes, enabling healthcare professionals to make timely treatment decisions and optimize anticoagulation therapy.

The main technologies used in POC coagulation testing are optical, mechanical, and electrochemical. Optical technology utilizes light for various applications, including data transfer, imaging, and sensing. These tests are distributed through channels such as direct tenders and retail to end-users such as hospitals, clinics, and home care settings.

The point-of-care (POC) coagulation testing market research report is one of a series of new reports that provides point-of-care (POC) coagulation testing market statistics, including point-of-care (POC) coagulation testing industry global market size, regional shares, competitors with a point-of-care (POC) coagulation testing market share, detailed point-of-care (POC) coagulation testing market segments, market trends and opportunities, and any further data you may need to thrive in the point-of-care (POC) coagulation testing industry. This point-of-care (POC) coagulation testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The point-of-care (POC) coagulation testing market consists of revenues earned by entities by providing coagulation testing services, on-site hemostasis testing, point-of-care diagnostic services, and rapid coagulation analysis. The market value includes the value of related goods sold by the service provider or included within the service offering. The point-of-care (POC) coagulation testing market also includes sales of coagulation analyzers, test strips, prothrombin time (PT) monitors, D-dimer testing devices, and point-of-care coagulation testing kits. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.